D-0084-2024 Class II Terminated

Recalled by SUN PHARMACEUTICAL INDUSTRIES INC — Princeton, NJ

FDA drug recall D-0084-2024 was initiated by SUN PHARMACEUTICAL INDUSTRIES INC on Oct 20, 2023 and is designated Class II. Reason for recall: Failed Impurities/Degradation Specifications. The recall status is terminated (terminated Jul 25, 2024). Affected quantity: 2304 Bottles.

Recall details

Product Type
Drugs
Report Date
Nov 8, 2023
Initiation Date
Oct 20, 2023
Termination Date
Jul 25, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
2304 Bottles

Product description

Liothyronine Sodium Tablets, USP, 25 mcg, 100-count bottles, Rx only, Distributed by: Sun Pharmaceutical Industries, Inc.Cranbury, NJ 08512, Manufactured by: Sun Pharmaceutical Industries Ltd. Survey No. 259/15, Dadra-396 191,(U.T. of D & NH), India. NDC 62756-590-88

Reason for recall

Failed Impurities/Degradation Specifications.

Distribution pattern

Nationwide within the United States

Code information

Lot #: DNC2204A, Exp. Date 11/2023

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0084-2024
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0084-2024. Report a data issue: hello@regdatalab.com.